Humanigen is not currently accepting enquiries regarding lenzilumab™ for emergency use.

Humanigen has announced positive Phase 3 topline results in Patients with COVID-19. For more information, view our press release or visit ClinicalTrials.gov (Identifier: NCT04351152)

See also:

Mayo Clinic Study of Humanigen’s Lenzilumab Shows Rapid Recovery and Discharge in Severe and Critical COVID-19 Patients (more information)

Humanigen Reports Additional Analysis of Lenzilumab in Severe and Critical COVID-19 Patients (more information)

Follow Us

  • Twitter
  • LinkedIn
  • Facebook

©2021 Humanigen, Inc.  All rights reserved